3 Biotech Penny Stocks You Should Know About Right Now
While the broader stock market is down today, there are plenty of penny stocks that are pushing up right now. And, over the past few months, many investors have been focused on biotech penny stocks. There are a few good reasons for the rise of the biotech industry during that time and the subsequent bullish momentum we’ve witnessed. To understand it fully, we have to take a closer look at the current state of the stock market.
Right now, the main impacting factor is Covid and the resulting impact of the pandemic. While Covid cases are declining, in the U.S., we are witnessing a sizable amount of inflation. In addition, today, the Chinese housing market took a major hit, resulting in a large bearish trend around the world. However, given that the pandemic is still in focus, many biotech penny stocks have been rising as a result.
This includes Zivo Bioscience Inc. (NASDAQ: ZIVO), which managed to climb by over 165% at midday. While no news caused this gain, the company experienced a volume spike of 56 million shares by 10:50 AM EST, compared to its 65-day average of roughly 214,000 shares. This is a major increase and shows both how speculative the stock market is right now, and the hype around ZIVO stock.
So, looking at all of this, we see that the stock market is in a highly volatile place right now. And as a result, there is plenty of momentum to take advantage of. Considering this, let’s take a look at three biotech penny stocks to watch in September 2021.
3 Biotech Penny Stocks to Watch in September 2021
Clovis Oncology Inc. (NASDAQ: CLVS)
Clovis Oncology Inc. is a biotech penny stock that has shot up by around 9% in the past month. If you’re not familiar, this company acquires, develops, and commercializes anti-cancer products. The company’s current offerings include Rubraca, which is for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Its products are offered through pharmacies and distributors to both health care providers and patients. Clovis actively has agreements for licenses with Pfizer Inc. and AstraZeneca UK Limited. Because of its broad market scope, Clovis remains a popular choice for investors of all types.
At the tail end of August, Clovis announced the availability of and reimbursement for Rubraca tables for women with relapsed ovarian cancer in Switzerland. This offers a new maintenance treatment option for eligible women with the condition. Rubraca showed a statistically large improvement in progression-free survival versus the placebo in all ovarian patients that were a part of the study.
“There has been a significant need for additional treatment options for women with relapsed ovarian cancer, and we are proud that women who may benefit will have access to rucaparib. We remain committed to making rucaparib available to eligible patients in the US and Europe.”President and CEO of Clovis, Patrick J. Mahaffy
Since this update was released, CLVS stock has understandably gone up in market value. Considering this, will CLVS stock be on your list of penny stocks to watch as we continue through September?
Viveve Medical Inc. (NASDAQ: VIVE)
One of the bigger gainers of the day so far is VIVE stock. By midday, shares of VIVE had shot up by over 10%. Despite some less than stellar trading performance in the past year, the recent bullish turnaround could be good news for the company.
Today, a 510(k) form was released premarket which is likely the reason for its big gain. For some context, a 510(k) is a medical device registration submission to the FDA. The registration is for its Viveve Medical System and Viveve 2.0 system. Aside from this, VIVE reported its Q2 2021 financials back in August. In the results, the company reported $1.7 million in revenue and a per-unit sales increase of 42% quarter-over-quarter for its consumable treatment tips. In addition, it stated that it is on track for enrollment in its Pivotal SUI PURSUIT trial.
“During the second quarter of 2021, Viveve continued its focus on advancing its stress urinary incontinence (SUI) clinical development program…We are pleased with our progress as we continue to execute our development program toward a potential SUI indication in the U.S.”The CEO of Viveve, Scott Durbin
All of this is great news for the company and shows that it is working hard to continue growing. With that in mind, do you think that VIVE stock is worth adding to your penny stocks watchlist?
Aikido Pharma Inc. (NASDAQ: AIKI)
Aikido Pharma Inc. is a biotech penny stock that develops therapeutics for treating cancer patients. These are small-molecule products for treating pancreatic cancer, acute lymphoblastic leukemia, and acute myeloid leukemia. One of its products is DHA-dFdC which is a pancreatic drug candidate. It also has KPC34 for treating leukemia. Additionally, Aikido is developing an antiviral platform to inhibit replication of COVID-19, Ebolavirus, and more. Its ties to the pandemic could help to explain the recent momentum that AIKI stock has had. In the past twelve months, shares of AIKI have climbed by a respectable 27% or so.
On August 6th, the company announced an update on its use of machine learning to support its antiviral platform with the University Of Maryland Baltimore School Of Medicine. The company’s goal for the project is to identify and optimize anti-viral compounds that inhibit viral replication by targeting a protein complex degrading RNA at the cellular level.
To support its goal, SlicsBio LLC is using its physics-based machine learning to accelerate the discovery of broad-spectrum antivirals. Grollman-Glick Professor of Pharmaceutical Sciences and CSO of SlicsBio, Alex MacKerell said, “Towards addressing the global Covid-19 pandemic SilcsBio, LLC has partnered with Aikido Pharmaceuticals by applying its proprietary technology towards the development of novel broad-spectrum antivirals that will also be effective towards other viruses, including Influenza, Ebola, and Marburg.” With all of this new information considered, will AIKI stock make your watchlist this week?
Will Biotech Penny Stocks Make Gains in a Bear Market?
Understanding how to make money in a bear market is something that those who invest in penny stocks can benefit from. While it can be difficult, having an investing strategy and a strong understanding of your portfolio goals can both work in tandem to help you make money with penny stocks despite market conditions.
So, considering that there is so much going on in the world right now, there is a sizable amount of momentum to take advantage of. With that in mind, which biotech penny stocks are on your watchlist right now?